Tag:

generic competition

Latest Headlines

Latest Headlines

With Provigil exclusivity, Teva may hike its forecast

Teva can reap sales of branded Provigil, and it can profit from the generic version.

Forest mourns as Teva celebrates launch of generic Lexapro

Forest Laboratories ($FRX) could well be playing a dirge at corporate headquarters today. The company's leading drug, Lexapro, now has new generic competition.

Sanofi to shutter Plavix-producing U.K. plant

Generic competition has claimed another pharma plant. Sanofi ($SNY) plans to shutter a U.K. manufacturing facility by 2015, as demand erodes for products made there. Some 450 people work at the plant,  Sky 's Tyne and Wear edition reports, and after higher-ups announced the closure plans Wednesday, the stunned workers went home for the day

AstraZeneca sues FDA to block Seroquel copies

AstraZeneca is seeking an injunction to block Seroquel copies at least until a court can review its claims. The drugmaker says the FDA shouldn't be allowed to usher generic Seroquel onto the market until Dec. 2, when data exclusivity expires.

With Seroquel petition denied, AZ needs M&A

The FDA has officially denied AstraZeneca's petition to hold off generic versions of its antipsychotic drug Seroquel.

Health plans sue Big Pharma over co-pay coupons

Pharma's co-pay discounts have their fans--patients, certainly, but they also have their detractors.

Wyeth puts $960M squeeze on Sun for Protonix launch

Sun Pharmaceuticals ' at-risk launch of generic Protonix may prove to have been risky indeed. Pfizer's ($PFE) Wyeth unit slapped the Indian drugmaker with a $960 million damages claim, alleging Sun's

WellPoint to drop branded Lipitor from its formulary

Lipitor just got shot down by a healthcare plan. As The Wall Street Journal reports, WellPoint ($WLP) is planning to stop covering Pfizer's ($PFE) brand-name cholesterol drug April 1, favoring its

Novartis CEO calls external focus key to fast-changing pharma

The idea of facing generic competition for a $5 billion blockbuster like Diovan would daunt almost any CEO. But Joe Jimenez (photo) says his experience hawking baby food and ketchup at Heinz made him

Gloom for the pharma industry, yes. Doom? No

AstraZeneca's ($AZN) layoffs announcement yesterday touched off more than its share of hand-wringing. It may be a straw-that-broke-the-camel's-back case; this shedding of 7,300 jobs follows a spate